MRI detection of free-contrast agent nanoparticles.
CSI
MRI
liposomes
micelles
nanoemulsions
nanoparticles
Journal
Magnetic resonance in medicine
ISSN: 1522-2594
Titre abrégé: Magn Reson Med
Pays: United States
ID NLM: 8505245
Informations de publication
Date de publication:
29 Sep 2024
29 Sep 2024
Historique:
revised:
29
07
2024
received:
23
04
2024
accepted:
25
08
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
aheadofprint
Résumé
The integration of nanotechnology into biomedical imaging has significantly advanced diagnostic and theranostic capabilities. However, nanoparticle detection in imaging relies on functionalization with appropriate probes. In this work, a new approach to visualize free-label nanoparticles using MRI and MRS techniques is described, consisting of detecting by Three different nanosystems, namely lipid-based micelles, liposomes, and perfluorocarbon-based nanoemulsions, were synthesized, characterized by high resolution NMR and then visualized by The study successfully demonstrates the feasibility of detecting nanoparticles using MRI/MRS without probe functionalization, employing These findings present a promising avenue for nanoparticle imaging in biomedical applications, offering potential enhancements to diagnostic and theranostic procedures. This non-invasive approach has the capacity to advance imaging techniques and expand the scope of nanoparticle-based biomedical research. Further exploration is necessary to fully explore the implications and applications of this method.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
Organisme : AIRC
ID : IG-22041
Organisme : University of Torino
Informations de copyright
© 2024 The Author(s). Magnetic Resonance in Medicine published by Wiley Periodicals LLC on behalf of International Society for Magnetic Resonance in Medicine.
Références
Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez‐Chapa SO. Nanotechnology for COVID‐19: therapeutics and vaccine research. ACS Nano. 2020;14:7760‐7782.
Crommelin DJA, van Hoogevest P, Storm G. The role of liposomes in clinical nanomedicine development. What now? Now what? J Control Release. 2020;318:256‐263.
Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol. 2013;24:1159‐1166.
Han X, Xu K, Taratula O, Farsad K. Applications of nanoparticles in biomedical imaging. Nanoscale. 2019;11:799‐819.
Harshita BMA, Das SS, Pottoo FH, Beg S, Rahman Z. Lipid‐based Nanosystem As intelligent carriers for versatile drug delivery applications. Curr Pharm des. 2020;26:1167‐1180.
Lohrke J, Frenzel T, Endrikat J, et al. 25 years of contrast‐enhanced MRI: developments, current challenges and future perspectives. Adv Ther. 2016;33:1‐28.
Vangijzegem T, Lecomte V, Ternad I, et al. Superparamagnetic iron oxide nanoparticles (SPION): from fundamentals to state‐of‐the‐art innovative applications for cancer therapy. Pharmaceutics. 2023;15:236.
Tirotta I, Dichiarante V, Pigliacelli C, et al. (19)F magnetic resonance imaging (MRI): from design of materials to clinical applications. Chem Rev. 2015;115:1106‐1129.
Kurhanewicz J, Vigneron DB, Ardenkjaer‐Larsen JH, et al. Hyperpolarized 13C MRI: path to clinical translation in oncology. Neoplasia. 2019;21:1‐16.
Doan VHM, Nguyen VT, Mondal S, et al. Fluorescence/photoacoustic imaging‐guided nanomaterials for highly efficient cancer theragnostic agent. Sci Rep. 2021;11:15943.
van der Meulen NP, Strobel K, Lima TVM. New radionuclides and technological advances in SPECT and PET scanners. Cancer. 2021;13:6183.
Man F, Lammers T, de Rosales TM. Imaging Nanomedicine‐based drug delivery: a review of clinical studies. Mol Imaging Biol. 2018;20:683‐695.
De Feyter HM, de Graaf RA. Deuterium metabolic imaging – Back to the future. J Magn Reson. 2021;326:106932.
Cohen SM, Shulman RG, McLaughlin AC. Effects of ethanol on alanine metabolism in perfused mouse liver studied by 13C NMR. Proc Natl Acad Sci U S A. 1979;76:4808‐4812.
Öz G, Alger JR, Barker PB, et al. Clinical proton MR spectroscopy in central nervous system disorders. Radiology. 2014;270:658‐679.
Weinberg BD, Kuruva M, Shim H, Mullins ME. Clinical applications of magnetic resonance spectroscopy in brain tumors. Radiol Clin North Am. 2021;59:349‐362.
Guilfoyle DN, Mansfield P. Chemical‐shift imaging. Magn Reson Med. 1985;2:479‐489.
Brown TR. Practical applications of chemical shift imaging: practical applications of CSI. NMR Biomed. 1992;5:238‐243.
Cunningham CH, Lau JYC, Chen AP, et al. Hyperpolarized 13 C metabolic MRI of the human heart: initial experience. Circ Res. 2016;119:1177‐1182.
Grist JT, Chen M, Collier GJ, et al. Hyperpolarized129 Xe MRI abnormalities in dyspneic patients 3 months after COVID‐19 pneumonia: preliminary results. Radiology. 2021;301:E353‐E360.
Wang J, Merritt ME, Sherry AD, Malloy CR. Accelerated chemical shift imaging of hyperpolarized 13 C metabolites. Magn Reson Med. 2016;76:1033‐1038.
Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine. 2011;6:715‐728.
Hu W, Mao A, Wong P, et al. Characterization of 1,2‐Distearoyl‐ sn ‐glycero‐3‐phosphoethanolamine– N ‐[Methoxy(polyethylene glycerol)‐2000] and its complex with doxorubicin using nuclear magnetic resonance spectroscopy and molecular dynamics. Bioconjug Chem. 2017;28:1777‐1790.
McRobbie DW, Moore EA, Graves MJ, Prince MR. MRI from Picture to Proton. Cambridge University Press; 2017. doi:10.1017/9781107706958
Alvares RDA, Hasabnis A, Prosser RS, Macdonald PM. Quantitative detection of PEGylated biomacromolecules in biological fluids by NMR. Anal Chem. 2016;88:3730‐3738.
Alvares RDA, Lau JYC, Macdonald PM, Cunningham CH, Prosser RS. Direct quantitative 13C‐filtered 1H magnetic resonance imaging of PEGylated biomacromolecules in vivo: quantitative 1H MRI of 13C‐PEGylated biomacromolecules. Magn Reson Med. 2017;77:1553‐1561.
Parton T, King L, Van Asperen J, Nesbitt A. Determination of 40 kDa polyethylene glycol (PEG) excretion after subcutaneous administration of certolizumab pegol to rats: P‐096. Inflamm Bowel Dis. 2008;14:S37.
Parton T, King L, Parker G, Nesbitt A. The PEG moiety of certolizumab pegol is rapidly cleared from the blood of humans by the kidneys once it is cleaved from the Fab': P‐0167. Inflamm Bowel Dis. 2009;15:S56.
Elliott VL, Edge GT, Phelan MM, et al. Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies. Mol Pharm. 2012;9:1291‐1301.
Forest T, Xu Q, Kuruvilla S, et al. Magnetic resonance and ultrastructural characterization of PEGylation‐associated vacuolation in nonclinical models. Toxicol Pathol. 2017;45:604‐613.
Hancu I, Dixon WT, Woods M, Vinogradov E, Sherry AD, Lenkinski RE. CEST and PARACEST MR contrast agents. Acta Radiol Stockh Swed. 2010;1987:910‐923.
He H, Zhao K, Xiao L, et al. Detection and chiral recognition of α‐hydroxyl acid through 1 H and CEST NMR spectroscopy using a ytterbium macrocyclic complex. Angew Chem Int Ed. 2019;58:18286‐18289.
Zhang X, Yuan Y, Li S, et al. Free‐base porphyrins as CEST MRI contrast agents with highly upfield shifted labile protons. Magn Reson Med. 2019;82:577‐585.
Zavaleta C, Ho D, Chung EJ. Theranostic nanoparticles for tracking and monitoring disease state. SLAS Technol. 2018;23:281‐293.
Koshkina O, Rheinberger T, Flocke V, et al. Biodegradable polyphosphoester micelles act as both background‐free 31P magnetic resonance imaging agents and drug nanocarriers. Nat Commun. 2023;14:4351.
Vuković L, Khatib FA, Drake SP, et al. Structure and dynamics of highly PEG‐ylated sterically stabilized micelles in aqueous media. J Am Chem Soc. 2011;133:13481‐13488.
Garello F, Boido M, Miglietti M, et al. Imaging of inflammation in spinal cord injury: novel insights on the usage of PFC‐based contrast agents. Biomedicine. 2021;9:379. doi:10.3390/biomedicines9040379
Liu G, Moake M, Har‐el YE, et al. In vivo multicolor molecular MR imaging using diamagnetic chemical exchange saturation transfer liposomes. Magn Reson Med. 2012;67:1106‐1113.
Yamaji Y, Akita S, Akita H, et al. Development of a mouse model for the visual and quantitative assessment of lymphatic trafficking and function by in vivo imaging. Sci Rep. 2018;8:5921.
Harrell MI, Iritani BM, Ruddell A. Tumor‐induced sentinel lymph node Lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol. 2007;170:774‐786.
Flögel U, Ding Z, Hardung H, et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation. 2008;118:140‐148.
Rizzitelli S, Giustetto P, Faletto D, Delli Castelli D, Aime S, Terreno E. The release of doxorubicin from liposomes monitored by MRI and triggered by a combination of US stimuli led to a complete tumor regression in a breast cancer mouse model. J Control Release. 2016;230:57‐63.
Ahrens ET, Helfer BM, O'Hanlon CF, Schirda C. Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine‐19 MRI. Magn Reson Med. 2014;72:1696‐1701.
Ruiz‐Cabello J, Walczak P, Kedziorek DA, et al. In vivo “hot spot” MR imaging of neural stem cells using fluorinated nanoparticles: 19 F stem cell imaging. Magn Reson Med. 2008;60:1506‐1511.
Cabral H, Kataoka K. Progress of drug‐loaded polymeric micelles into clinical studies. J Control Release. 2014;190:465‐476.
Saif MW, Podoltsev NA, Rubin MS, et al. Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest. 2009;28:186‐194.
Bogner W, Otazo R, Henning A. Accelerated MR spectroscopic imaging—a review of current and emerging techniques. NMR Biomed. 2021;34:e4314.
Diehl K‐H, Hull R, Morton D, et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol. 2001;21:15‐23.
Li H, Meade TJ. Molecular magnetic resonance imaging with Gd(III)‐based contrast agents: challenges and key advances. J Am Chem Soc. 2019;141:17025‐17041.